Chronic Fatigue Syndrome Clinical Trial
Official title:
Inspiratory Flow Dynamics During Sleep in Gulf War Syndrome (GWS) and the Effect of Continuous Positive Airway Pressure (CPAP)
The purpose of this study is to determine any sleep disordered breathing in veterans with
Gulf War Syndrome (GWS) and compare it to healthy normal asymptomatic Gulf War veterans.
This study will also determine the effect of treatment with continuous positive airway
pressure on veterans with Gulf War Syndrome.
1. The investigators hypothesize that sleep complaints (insomnia, un-refreshing sleep and
daytime fatigue) among GWS patients are related to increased sleep fragmentation
secondary to the presence of sleep disordered breathing in GWS patients.
2. The investigators hypothesize that increased collapsibility of the upper airway during
sleep with the development of inspiratory flow limitation (IFL) and sleep disordered
breathing causes the increased sleep fragmentation in GWS patients.
3. The investigators hypothesize that correction of IFL and sleep disordered breathing in
GWS patients will result in an improvement of their sleep quality resulting in an
improvement of their sleep complaints and other functional symptoms.
Hypothesis 1: To demonstrate that compared to Gulf War Veterans without GWS, GWS patients
have decreased total sleep and increased sleep fragmentation due to the presence of sleep
disordered breathing
In order to accomplish this goal and subsequent goals, we will assemble two samples of Gulf
War veterans. The first will be a sample of male GWS patients and the second will be a
sample of male Gulf War veterans without GWS (Gulf War veteran control group).
All of the GWS patients will be registered in the Gulf War Veterans Registry. To avoid
referral bias favoring the presence of IFL during sleep and sleep disordered breathing, we
will enroll GWS patients by contacting them from the Registry and inviting them to
participate. Gulf War veteran controls will be recruited in the same way and by
advertisement. Prospective study participants will be screened on several self-report
instruments to determine eligibility and assignment to the GWS group or to the Gulf War
veteran control group.
Criteria for assignment to the GWS group are scores above the designated clinical cutpoint
on each of three instruments measuring , fatigue, pain and cognitive dysfunction.
1. Fatigue during the preceding week will be assessed using the fatigue severity scale, a
10-item instrument measuring the level of disability related to fatigue (increasing
disability rated 1-7).
2. Pain during the preceding week will be assessed using a pain visual analog scale (VAS;
increasing pain rated 0-10 ).
3. Cognitive dysfunction during the preceding week, increasing difficulty with memory,
ability to think, and ability to concentrate will be assessed by VAS (increasing
cognitive dysfunction rated 0-10 ).
Conversely, criteria for assignment to the GW Veteran control group will require scores in
the non-clinical range on each of those instruments. Every subject will have a full night
polysomnogram.
Hypothesis 2: To demonstrate that the presence of IFL and sleep disordered breathing during
sleep among GWS patients distinguishes them from Gulf War veterans without GWS
A second sleep study will be used to accomplish this second objective. Using precise
methods, we will quantify the prevalence of IFL during sleep in GWS patients and in Gulf War
veteran controls. Following completion, each study will be staged using Rechtschaffen and
Kales criteria. From each study, 3 three minute periods of continuous NREM sleep (a total of
approximately 120 breaths) will be randomly selected and analyzed for the prevalence of flow
limited breaths. During the three minute periods, all of the breaths will be analyzed
whether they occur during sleep or during brief (< 15 second) arousals.
Hypothesis 3: To demonstrate that relief of IFL during sleep and sleep disordered breathing
will result in improvement of the functional symptoms of GWS patients
We will accomplish this utilizing a masked parallel group of sham-control and treatment
trial of nasal continuous positive airway pressure (CPAP) in GWS patients. Functional
symptoms ( fatigue, pain and cognitive dysfunction) will be assessed using validated,
self-report questionnaires and daily ratings of symptoms.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05454683 -
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT02075489 -
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
|
N/A | |
Completed |
NCT01686074 -
Motor Control in Chronic Fatigue Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT01651754 -
Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT00540254 -
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00071162 -
Genetics of Fibromyalgia
|
N/A | |
Withdrawn |
NCT04870476 -
Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome
|
N/A | |
Completed |
NCT05730660 -
Quercetin Phytosome® Chronic Fatigue Syndrome
|
N/A | |
Recruiting |
NCT04542161 -
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
Phase 2 | |
Recruiting |
NCT03807973 -
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
|
Phase 1 | |
Recruiting |
NCT05719493 -
Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)
|
N/A | |
Recruiting |
NCT05967052 -
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
|
Phase 2 | |
Terminated |
NCT01730495 -
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01156909 -
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01650636 -
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
|
N/A | |
Completed |
NCT01046370 -
A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT06128967 -
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
|
Phase 3 | |
Completed |
NCT02669212 -
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
|
N/A | |
Not yet recruiting |
NCT06011135 -
Exploring Worry in CFS/ME
|